Which AI agents work with Endo Cvd Risk Assessment Cured Cushing General Population?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Endo Cvd Risk Assessment Cured Cushing General Population?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Cvd Risk Assessment Cured Cushing General Population by dromlakhani

Name: Endo Cvd Risk Assessment Cured Cushing General Population
Rating: 4.5 (4 reviews)
Author: dromlakhani

Endo Cvd Risk Assessment Cured Cushing General Population

The guideline recommends that cardiovascular risk assessment and management in adults with cured Cushing syndrome follow the same approach as in the general population. Clinical triggers include evaluating a patient with cured Cushing syndrome, performing post-treatment cardiovascular risk assessment in Cushing, and planning long-term follow-up for cured endocrine disorders.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Cardiovascular risk assessment and treatment approach same as general population for cured Cushing syndrome

STEP 1 — Gather Information

Collect traditional risk factors (age, sex, smoking status, systolic blood pressure, antihypertensive use, total cholesterol, HDL-C, diabetes status) and calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations.

STEP 2 — Rule In / Rule Out

If 10-year ASCVD risk is ≥20%, classify as high risk and recommend high-intensity statin therapy; if risk is <20%, proceed to further stratification.

STEP 3 — Classify or Stratify

For risk <20%, categorize as low (<5%), borderline (5–7.4%), or intermediate (7.5–19.9%) and assess for risk-enhancing factors (e.g., family history of premature ASCVD, LDL‑C ≥160 mg/dL, metabolic syndrome, chronic kidney disease, lipoprotein(a) ≥50 mg/dL).

STEP 4 — Decide

Low risk (<5%): advise lifestyle modification only. Borderline risk (5–7.4%): if risk‑enhancing factors are present, discuss statin initiation; if coronary artery calcium (CAC) score is zero, may favor withholding statin. Intermediate risk (7.5–19.9%): discuss moderate‑ or high‑intensity statin based on risk‑enhancing factors and patient preference. High risk already addressed in Step 2.

Clinical Guardrails / Mimics / Pitfalls

Do not assume cured Cushing syndrome automatically warrants different CV risk assessment; do not omit traditional risk factor evaluation; avoid overtreating based on presumed endocrine‑related risk without calculation; do not neglect lifestyle modifications; reassess for disease recurrence if symptoms return.

Concrete Clinical Example

A 45‑year‑old woman with cured Cushing syndrome (post‑surgical remission, normal cortisol) presents for follow‑up. She is a non‑smoker, BP 128/82 mmHg, total cholesterol 210 mg/dL, HDL‑C 55 mg/dL, LDL‑C 130 mg/dL, no diabetes. Pooled Cohort Equations give 10‑year ASCVD risk ≈5.2% (borderline). No family history of premature ASCVD, lipoprotein(a) 30 mg/dL, no metabolic syndrome. Lifestyle modification is advised; statin not initiated but discussed; repeat lipids in 6‑12 months.

Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

---name: endo-cvd-risk-assessment-cured-cushing-general-populationdescription: The guideline recommends that cardiovascular risk assessment and management in adults with cured Cushing syndrome follow the same approach as in the general population. Clinical triggers include evaluating a patient with cured Cushing syndrome, performing post-treatment cardiovascular risk assessment in Cushing, and planning long-term follow-up for cured endocrine disorders.---# Cardiovascular risk assessment and treatment approach same as general population for cured Cushing syndrome## STEP 1 — Gather InformationCollect traditional risk factors (age, sex, smoking status, systolic blood pressure, antihypertensive use, total cholesterol, HDL-C, diabetes status) and calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations.## STEP 2 — Rule In / Rule OutIf 10-year ASCVD risk is ≥20%, classify as high risk and recommend high-intensity statin therapy; if risk is <20%, proceed to further stratification.## STEP 3 — Classify or StratifyFor risk <20%, categorize as low (<5%), borderline (5–7.4%), or intermediate (7.5–19.9%) and assess for risk-enhancing factors (e.g., family history of premature ASCVD, LDL‑C ≥160 mg/dL, metabolic syndrome, chronic kidney disease, lipoprotein(a) ≥50 mg/dL).## STEP 4 — DecideLow risk (<5%): advise lifestyle modification only. Borderline risk (5–7.4%): if risk‑enhancing factors are present, discuss statin initiation; if coronary artery calcium (CAC) score is zero, may favor withholding statin. Intermediate risk (7.5–19.9%): discuss moderate‑ or high‑intensity statin based on risk‑enhancing factors and patient preference. High risk already addressed in Step 2.## Clinical Guardrails / Mimics / PitfallsDo not assume cured Cushing syndrome automatically warrants different CV risk assessment; do not omit traditional risk factor evaluation; avoid overtreating based on presumed endocrine‑related risk without calculation; do not neglect lifestyle modifications; reassess for disease recurrence if symptoms return.## Concrete Clinical ExampleA 45‑year‑old woman with cured Cushing syndrome (post‑surgical remission, normal cortisol) presents for follow‑up. She is a non‑smoker, BP 128/82 mmHg, total cholesterol 210 mg/dL, HDL‑C 55 mg/dL, LDL‑C 130 mg/dL, no diabetes. Pooled Cohort Equations give 10‑year ASCVD risk ≈5.2% (borderline). No family history of premature ASCVD, lipoprotein(a) 30 mg/dL, no metabolic syndrome. Lifestyle modification is advised; statin not initiated but discussed; repeat lipids in 6‑12 months.**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674

Frequently asked questions